iDEL Therapeutics
PrivateLast Round
Seed
Mar 17, 2026
Total Funding Raised
$20.87M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
iDEL Therapeutics is a biotechnology company developing a pipeline of cancer therapeutics that are delivered directly into the cytosol of tumor cells using a proprietary synthetic shuttle platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
iDEL Therapeutics Comparables
Compare iDEL Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Xelcis Bio, Inc. | 87% | |
| Libera Bio | 86% | |
| CyGenica | 84% |
iDEL Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Mar 17, 2026 | ||||
| Seed | Mar 17, 2026 |
iDEL Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NRW.Venture | Seed |
| KHAN Technology Transfer Fund II | Seed |
| BioMedPartners | Seed |
| Gründerfonds Ruhr | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 17, 2026
$11M raised in Seed round.
iDEL Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access